FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

24 Jul 15

Cancer Genetics, Inc. Announced Today That it Has Suspended Its Activity on the "At-The-Market" Equity Offering (read more...)

- RUTHERFORD, N.J., July 24, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based (read more...)
16 Jul 15

Cancer Genetics, Inc. Announces the Expansion of Access to Its Proprietary Diagnostic Tests Through Agreement With Harvard Pilgrim Healthcare (read more...)

- RUTHERFORD, N.J., July 16, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based (read more...)

Events

02 Jul 15

Clinical Utility & Interpretation of FISH Probes for Effective Diagnosis of Cervical Cancer

04 Jun 15

Jefferies 2015 Global Healthcare Conference

29 May 15

ASCO 2015 Annual Meeting

Clinicians
Patients